ADC Therapeutics (ADCT) Non Operating Income (2019 - 2023)
Historic Non Operating Income for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$9.3 million.
- ADC Therapeutics' Non Operating Income rose 8080.49% to -$9.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$30.4 million, marking a year-over-year decrease of 4081.88%. This contributed to the annual value of -$31034.0 for FY2022, which is 40380.81% down from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Non Operating Income is -$9.3 million, which was up 8080.49% from -$13.0 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Non Operating Income registered a high of $32.1 million during Q3 2020, and its lowest value of -$81.5 million during Q2 2020.
- Moreover, its 5-year median value for Non Operating Income was $562.0 (2019), whereas its average is -$5.7 million.
- The largest annual percentage gain for ADC Therapeutics' Non Operating Income in the last 5 years was 181328983.05% (2020), contrasted with its biggest fall of 1287592938.39% (2020).
- Over the past 5 years, ADC Therapeutics' Non Operating Income (Quarter) stood at $562.0 in 2019, then soared by 5711109.96% to $32.1 million in 2020, then plummeted by 99.98% to $6429.0 in 2021, then plummeted by 247.02% to -$9452.0 in 2022, then tumbled by 97794.63% to -$9.3 million in 2023.
- Its Non Operating Income was -$9.3 million in Q3 2023, compared to -$13.0 million in Q2 2023 and -$8.1 million in Q1 2023.